Chinese scientists publish antidote for ADE from COVID vaccines

Sharing is Caring!

Yep. They’re one step ahead, for sure. And of course they are since they released this bioweapon.

There’s two new studies – one that explains how the COVID-19 vaccines are beginning to cause ADE and what is happening. The second is a proposed antidote.

So first, the original study. They’re not calling it ADE. They’re calling it, “ Antibody Dependent Auto-Attack (ADAA)”.

The current study revealed the pathogenic roles and the new mechanism of action (ADAA) of certain antibodies specific to the spike proteins of coronaviruses such as the COVID-19 virus and the SARS-CoV virus (Figure 8). We had discovered that in a mouse model, pre-injection of anti-influenza immune sera induced more severe infections than the mice infected with an influenza virus alone . Wang and co-workers reported that anti-SARS-CoV spike antisera promoted SARS infection through antibody-dependent enhancement (ADE) in vitro. Liu and co-workers reported that anti-SARS-CoV spike immune sera induced by a SARS-CoV vaccine caused acute lung injury by promoting MCP1 and IL-8 production and monocyte or macrophage recruitment and accumulation in SARS-CoV infected macaque models . The previously reported mechanism of action (MOA) of these anti-spike antibodies is ADE-based, in that the antibodies enhance viral infectivity.

See also  The New York Times’ Latest Lie About Covid Is HILARIOUS!

And now for the antidote.

A drug candidate for treating adverse reactions caused by pathogenic antibodies inducible by COVID-19 virus and vaccines

In a recent study, we reported that certain anti-spike antibodies of COVID-19 and SARS-CoV viruses can have a pathogenic effect through binding to sick lung epithelium cells and misleading immune responses to attack self-cells. We termed this new pathogenic mechanism “Antibody Dependent Auto-Attack” (ADAA). This study explores a drug candidate for prevention and treatment of such ADAA-based diseases. The drug candidate is a formulation comprising N-acetylneuraminic acid methyl ester (NANA-Me), an analog of N-acetylneuraminic acid. NANA-Me acts through a unique mechanism of action (MOA) which is repairment of the missing sialic acid on sick lung epithelium cells.
This MOA can block the antibodies’ binding to sick cells, which are vulnerable to pathogenic antibodies. Our in vivo data showed that the formulation significantly reduced the sickness and deaths caused by pathogenic anti-spike antibodies. Therefore, the formulation has the potential to prevent and treat the serious conditions caused by pathogenic antibodies during a COVID-19 infection. In addition, the formulation has potential to prevent and treat the adverse reactions of COVID-19 vaccines because the vaccines can induce similar antibodies, including pathogenic antibodies. The formulation will be helpful in increasing the safety of the vaccines without reducing the vaccine’s efficacy.

Wait, I thought the vaccines were safe and effective?

I have an idea. How about instead of injecting an experimental vaccine that causes “pathogenic priming”, ADE, cytokine storms and death 6 to 12 months after the injection, then looking for an antidote.. isn’t it easier to just… not get injected?

h/t Shaun Kaven

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.